Compare Glenmark Pharma with Torrent Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs TORRENT PHARMA - Comparison Results

GLENMARK PHARMA     Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

TORRENT PHARMA 
   Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA TORRENT PHARMA GLENMARK PHARMA/
TORRENT PHARMA
 
P/E (TTM) x 12.2 58.7 20.7% View Chart
P/BV x 1.7 6.2 28.0% View Chart
Dividend Yield % 0.6 0.8 67.4%  

Financials

 GLENMARK PHARMA   TORRENT PHARMA
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-19
TORRENT PHARMA
Mar-18
GLENMARK PHARMA/
TORRENT PHARMA
5-Yr Chart
Click to enlarge
High Rs7121,550 45.9%   
Low Rs4841,144 42.3%   
Sales per share (Unadj.) Rs349.6354.7 98.6%  
Earnings per share (Unadj.) Rs32.840.1 81.8%  
Cash flow per share (Unadj.) Rs44.364.2 69.0%  
Dividends per share (Unadj.) Rs2.0014.00 14.3%  
Dividend yield (eoy) %0.31.0 32.2%  
Book value per share (Unadj.) Rs198.6273.1 72.7%  
Shares outstanding (eoy) m282.17169.22 166.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.73.8 45.0%   
Avg P/E ratio x18.233.6 54.2%  
P/CF ratio (eoy) x13.521.0 64.3%  
Price / Book Value ratio x3.04.9 61.0%  
Dividend payout %6.134.9 17.5%   
Avg Mkt Cap Rs m168,625227,897 74.0%   
No. of employees `00012.014.7 81.9%   
Total wages/salary Rs m20,56111,353 181.1%   
Avg. sales/employee Rs Th8,196.04,083.0 200.7%   
Avg. wages/employee Rs Th1,708.1772.3 221.2%   
Avg. net profit/employee Rs Th768.5461.3 166.6%   
INCOME DATA
Net Sales Rs m98,65560,021 164.4%  
Other income Rs m2,0812,988 69.6%   
Total revenues Rs m100,73663,009 159.9%   
Gross profit Rs m15,85813,493 117.5%  
Depreciation Rs m3,2594,086 79.8%   
Interest Rs m3,3463,085 108.5%   
Profit before tax Rs m11,3359,310 121.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1,6720-   
Tax Rs m3,7562,529 148.6%   
Profit after tax Rs m9,2506,781 136.4%  
Gross profit margin %16.122.5 71.5%  
Effective tax rate %33.127.2 122.0%   
Net profit margin %9.411.3 83.0%  
BALANCE SHEET DATA
Current assets Rs m66,96852,623 127.3%   
Current liabilities Rs m40,21152,022 77.3%   
Net working cap to sales %27.11.0 2,706.4%  
Current ratio x1.71.0 164.6%  
Inventory Days Days83120 69.7%  
Debtors Days Days8176 106.5%  
Net fixed assets Rs m33,32285,016 39.2%   
Share capital Rs m282846 33.3%   
"Free" reserves Rs m55,77045,376 122.9%   
Net worth Rs m56,05246,222 121.3%   
Long term debt Rs m35,73841,115 86.9%   
Total assets Rs m132,888142,432 93.3%  
Interest coverage x4.44.0 109.2%   
Debt to equity ratio x0.60.9 71.7%  
Sales to assets ratio x0.70.4 176.2%   
Return on assets %9.56.9 136.8%  
Return on equity %16.514.7 112.5%  
Return on capital %17.814.2 125.5%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m62,99814,580 432.1%   
Fx outflow Rs m22,8593,600 635.0%   
Net fx Rs m40,14010,980 365.6%   
CASH FLOW
From Operations Rs m13,2428,942 148.1%  
From Investments Rs m-6,990-47,070 14.9%  
From Financial Activity Rs m-7,38734,174 -21.6%  
Net Cashflow Rs m-2,971-3,655 81.3%  

Share Holding

Indian Promoters % 48.3 71.5 67.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 6.9 7.0 98.3%  
FIIs % 34.4 12.6 273.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 8.8 119.3%  
Shareholders   56,727 26,511 214.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   PFIZER  GSK PHARMA  PLETHICO PHARMA  WYETH LTD  ABBOTT INDIA  

Compare GLENMARK PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps 470 Points; Energy and Banking Stocks Witness Selling(Closing)

Indian share markets witnessed negative trading activity throughout the day and ended deep in the red. The BSE Sensex fell over 550 points intraday and breached the 36,000 mark.

Related Views on News

GLENMARK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of GLENMARK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 53.1% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, GLENMARK PHARMA has posted a net profit of Rs 1 bn (down 53.1% YoY). Sales on the other hand came in at Rs 23 bn (up 7.3% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 32.5% (Quarterly Result Update)

Jul 25, 2019 | Updated on Jul 25, 2019

For the quarter ended June 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 32.5% YoY). Sales on the other hand came in at Rs 20 bn (up 8.0% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 6.6% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 6.6% YoY). Sales on the other hand came in at Rs 26 bn (up 12.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 166.7% (Quarterly Result Update)

May 22, 2019 | Updated on May 22, 2019

For the quarter ended March 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 166.7% YoY). Sales on the other hand came in at Rs 19 bn (up 7.8% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Sep 19, 2019 03:35 PM

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA - J.B.CHEMICALS COMPARISON

COMPARE GLENMARK PHARMA WITH

MARKET STATS